Open access
Sep 2026
Prognostic Stratification in High‐Volume Metastatic Hormone‐Sensitive Prostate Cancer Treated With First‐Line Androgen Receptor Pathway Inhibitor–Based Combination Therapy
We aimed to stratify clinical risk among patients with high‐volume metastatic hormone‐sensitive prostate cancer (mHSPC) treated with first‐line androgen receptor pathway inhibitor (ARPI) plus androgen deprivation therapy (ADT).
Keiichiro Miyajima, T. Yanagisawa, Wataru Fukuokaya et al.
· International journal of uro... · 0 citations